期刊文献+

重度肥胖症合并2型糖尿病的诊断与治疗 被引量:9

Diagnosis and treatment of severe obesity complicated with type 2 diabetes mellitus
原文传递
导出
摘要 世界范围内肥胖症发病率逐年增加,WHO已将其定位为一种重要的疾病,它已成为世界范围内重要的公共卫生问题.国内调查结果显示:2002年我国成年人超重和肥胖症发生率分别为22.8%和7.1%,超重和肥胖症已经影响到2亿7千万人口.目前,代谢外科手术已成为治疗重度病态肥胖症安全而有效的新治疗手段.2011年7月中南大学湘雅三医院收治1例体质量148 kg,BMI为51 kg/m2,合并2型糖尿病的重度肥胖症患者.经术前组织多学科团队(MDT)协作诊断与治疗,拟定治疗方案;患者行腹腔镜胃袖状切除术.术后随访至2012年9月,患者体质量减至75 kg,BMI降低至25 kg/m2,术后恢复良好,无严重手术并发症发生. The incidence of obesity increases worldwide every year,positioned as an important disease by WHO,and it has become an important public health problem.National survey shows that overweight and obesity rates were 22.8% and 7.1% respectively in Chinese adults in 2002,affecting 270 million people.At present,bariatric surgery is a safe and effective treatment for severe obese patients.In July 2011,a patient with Ⅲ degree obesity (weight 148 kg and BMI 51 kg/m2) complicated with type 2 diabetes mellitus was admitted to the Third Xiangya Hospital of Central South University.The treatment plan was made after diagnosis and treatment of muhidisciplinary team and the patient underwent laparoscopic sleeve gastrectomy.The patient was followed up to September 2012 and recovered well without severe surgical complications,and the weight and BMI were decreased to 75 kg and 25 kg/m2 respectively.
出处 《中华消化外科杂志》 CAS CSCD 北大核心 2015年第7期590-592,共3页 Chinese Journal of Digestive Surgery
基金 湖南省自然科学基金面上项目(2015jj2155) 湖南省科技厅重点项目(2009sk4005)
关键词 肥胖症 糖尿病 2型 胃袖状切除术 腹腔镜检查 Obesity Sleeve gastrectomy Laparoscopy
  • 相关文献

参考文献11

二级参考文献139

共引文献361

同被引文献90

  • 1胡智阗,车念聪,夏蓉,袁梦.胰岛素抵抗与非酒精性脂肪性肝病关系的实验研究[J].首都医科大学学报,2009,30(2):218-221. 被引量:9
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)中国医学前沿杂志(电子版),2011;3:54-109.
  • 3Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy[J]. N Engl J Med, 2006, 355(23):2427-2443.
  • 4Kela R, Davies MJ. Treatment evaluation of liraglutide in type 2 diabetes[J]. Expert Opin Biol Ther, 2012, 12(I 1):1551.
  • 5Varanasi A, Patel P, Makdissi A, et aL Clinical use of lira- glutide in type 2 diabetes and its effects on cardiovascular risk factors[J]. Endocr Pratt, 2012, 18(2):140. .
  • 6Rossi ME, Nicolucd A. Liraglutide in type 2 diabetes:from pharmacological development to clinical practice[J]. Acta Biomed, 2009, 80(2):90-101.
  • 7Kundsen LR. Liraglutide:the therapeutic promise from ani- mal model[J]. Int J Clin Pract Suppl, 2010, 64(167):4-11.
  • 8Schmidt WE. Early clinical studies with liraglufide[J]. Int J Clin Pract Suppl, 2010, 64(167):12-20.
  • 9Dharmalingam M, Sriam U, Baruah MP. Liraglutide:A review of its therapeutic use as a once daily GLP- 1 analog for the management of type 2 diabetes mellitus[J]. Indian J Endocri- nol, 2011, 15(1):9-17.
  • 10Bode B. Liraglutide:a review of the frist once-daily GLP- 1 receptor, Am J Manag Care, 2011,17(2):$59-70.

引证文献9

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部